The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Open accessAbstract
Many drugs that are substrates of CYP3A4, the major human drug–metabolizing cytochrome P450 (CYP), show higher clearance in women than in men. Although this effect is believed to be related to drug metabolism, the underlying cause has not been elucidated. We investigated CYP3A4 in a large collection (n = 94) of well–characterized surgical liver samples and found 2–fold higher CYP3A4 levels in female compared with male samples (P < .0001) and a corresponding 50% increase in the CYP3A–dependent N–dealkylation of verapamil (P < .01). This expression difference was not due to preferential induction in women following higher drug exposure because it was even larger in a subgroup not previously exposed to drugs. Higher expression in women was also found for CYP3A4 messenger RNA (mRNA) transcripts, suggesting a pretranslational mechanism. Expression of the pregnane X receptor (PXR), which is crucially involved in CYP3A4 induction by xenobiotics, was strongly correlated to CYP3A4 at the mRNA level in all individuals as well as in the subgroup not exposed to drugs (r = 0.81; P < .0001), but no sex–dependent expression of PXR mRNA was found. The ABC transporter P–glycoprotein, which has been proposed to be implicated in the mechanism of sex–dependent drug clearance, was also not differentially expressed. The influence of drug treatment on expression was examined from patient drug histories, and strong induction of CYP3A4 by carbamazepine and St. John's wort was found. In conclusion, sex, in addition to PXR and drug exposure, is a major factor for CYP3A4 expression in humans, thus explaining many of the previous observations of sex–dependent drug clearance. (Hepatology 2003;38:978-988).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82245-5 · Cited by 3,489
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Self-citationThummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Self-citationPhenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene
Kawamoto, T., Sueyoshi, T., Zelko, I., Moore, R., Washburn, K., & Negishi, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6318 · Cited by 549
Gender Effects in Pharmacokinetics and Pharmacodynamics
Harris, R. Z., Benet, L. Z., & Schwartz, J. B. (1995) · Drugs · doi:10.2165/00003495-199550020-00003 · Cited by 506
How Important Are Gender Differences in Pharmacokinetics?
Meibohm, B., Beierle, I., & Derendorf, H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00002 · Cited by 454
The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
Tirona, R. G., Lee, W., Leake, B. F., Lan, L.-B., Cline, C. B., Lamba, V., Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., et al. (2003) · Nature Medicine · doi:10.1038/nm815 · Cited by 440
Effect of age and gender on the activity of human hepatic CYP3A
Hunt, C. M., Westerkam, W. R., & Stave, G. M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90010-g · Cited by 426
Phenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors
Sueyoshi, T., & Negishi, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.123 · Cited by 362
Diazepam disposition determinants
Greenblatt, D. J., Allen, M. D., Harmatz, J. S., & Shader, R. I. (1980) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1980.40 · Cited by 348
Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., & Guzelian, P. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113933 · Cited by 345
Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine: An Update
Spina, E., Pisani, F., & Perucca, E. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631030-00004 · Cited by 331
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor
Goodwin, B., Redinbo, M. R., & Kliewer, S. A. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 327
Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA
Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1108 · Cited by 314
Self-citationGenetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Self-citationSchuetz, E. G., Furuya, K. N., & Schuetz, J. D. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12089-2 · Cited by 265
Sex-Dependent Metabolism of Xenobiotics
Mugford, C. A., & Kedderis, G. L. (1998) · Drug Metabolism Reviews · doi:10.3109/03602539808996322 · Cited by 244
Women in Clinical Trials of New Drugs -- A Change in Food and Drug Administration Policy
Merkatz, R. B., Temple, R., Sobel, S., Feiden, K., & Kessler, D. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307223290429 · Cited by 234
Identification and functional characterization of eight CYP3A4 protein variants.
Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan, E., Hustert, E., Zanger, U. M., Brockmöller, J., Klenk, H., Meyer, U., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00008 · Cited by 234
Self-citationWandel, C., Kim, R., Wood, M., & Wood, A. (2002) · Anesthesiology · doi:10.1097/00000542-200204000-00019 · Cited by 215
Effects of age and gender on in vitro properties of human liver microsomal monooxygenases
Schmucker, D. L., Woodhouse, K. W., Wang, R. K., Wynne, H., James, O. F., McManus, M., & Kremers, P. (1990) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1990.164 · Cited by 207
Identification of P450 enzymes involved in metabolism of verapamil in humans
Kroemer, H., Gautier, J.-C., Beaune, P., Henderson, C., Roland Wolf, C., & Eichelbaum, M. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169164 · Cited by 200
Self-citationBasal Plasma Growth Hormone Levels in Man: New Evidence for Rhythmicity of Growth Hormone Secretion*
WINER, L. M., SHAW, M. A., & BAUMANN, G. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-6-1678 · Cited by 194
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
Tracy, T. S., Korzekwa, K. R., Gonzalez, F. J., & Wainer, I. W. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00923.x · Cited by 180
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics
Lew, K. H., Ludwig, E. A., Milad, M. A., Donovan, K., Jr., E. M., Ferry, J. J., & Jusko, W. J. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.167 · Cited by 169
Cummins, C. L., Wu, C., & Benet, L. Z. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128388 · Cited by 166
Heterotropic Cooperativity of Cytochrome P450 3A4 and Potential Drug-Drug Interactions
Tang, W., & Stearns, R. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338658 · Cited by 162
George, J., Byth, K., & Farrell, G. C. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00192-3 · Cited by 146
Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans
Jaffe, C. A., Turgeon, D. K., Lown, K. S., DeMott-Friberg, R., & Watkins, P. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00513.2001 · Cited by 129
Kinirons, M. T., O’Shea, D., Kim, R. B., Groopman, J. D., Thummel, K. E., Wood, A. J. J., & Wilkinson, G. R. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70029-9 · Cited by 128
DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY
Kahan, B. D., Kramer, W. G., Wideman, C. A., FLKCIINER, S. M., Lorber, M. I., & Buren, C. T. V. (1986) · Transplantation · doi:10.1097/00007890-198604000-00009 · Cited by 126
Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism
enp, J. M., Hall, S. D., Ring, B. J., Strom, S. C., & Wrighton, S. A. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00007 · Cited by 118
Lahuna, O., Rastegar, M., Maiter, D. M., Thissen, J., Lemaigre, F. P., & Rousseau, G. G. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.2.0423 · Cited by 112
Intersubject and dose‐related variability after intravenous administration of erythromycin.
Austin, K., Mather, L. E., Philpot, C. R., & McDonald, P. (1980) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1980.tb01755.x · Cited by 112
Kashuba, A. D. M., Bertino, J., Rocci, M. L., Kulawy, R., Beck, D. J., & Nafziger, A. N. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90175-8 · Cited by 106
Busse, D., Cosme, J., Beaune, P. H., Kroemer, H., Eichelbaum, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. F. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168924 · Cited by 105
Self-citationDrocourt, L., Pascussi, J., Assénat, E., Fabre, J.-M., Maurel, P., & Vilarem, M. (2001) · PubMed · Cited by 104
Race and sex influence clearance of nifedipine: Results of a population study
KRECICSHEPARD, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108678 · Cited by 104
STAT5 Signaling in Sexually Dimorphic Gene Expression and Growth Patterns
Davey, H. W., Wilkins, R. J., & Waxman, D. J. (1999) · The American Journal of Human Genetics · doi:10.1086/302599 · Cited by 95
Gender difference in ifosfamide metabolism by human liver microsomes
Schmidt, R., Baumann, F., Hanschmann, H., Geißler, F., & Preiß, R. (2001) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190396 · Cited by 93
Mdr1Limits CYP3A Metabolism in Vivo
Lan, L.-B., Dalton, J. T., & Schuetz, E. G. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.4.863 · Cited by 89
Transon, C., Lecoeur, S., Leemann, T., Beaune, P. H., & Dayer, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050164 · Cited by 82
Effects of Endogenous Steroids on CYP3A4-Mediated Drug Metabolism by Human Liver Microsomes
Nakamura, H., Nakasa, H., Ishii, I., Ariyoshi, N., Igarashi, T., Ohmori, S., & Kitada, M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.534 · Cited by 77
Effect of age and gender on tirilazad pharmacokinetics in humans
Hulst, L. K., Fleishaker, J. C., Peters, G. R., Harry, J. D., Wright, D. M., & Ward, P. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.45 · Cited by 74
Harris, R. Z., Tsunoda, S. M., Mroczkowski, P. J., Wong, H., & Benet, L. Z. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90112-5 · Cited by 64
Alterations in prednisolone disposition as a result of time of administration, gender and dose.
Meffin, P. J., Brooks, P., & Sallustio, B. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02363.x · Cited by 62
Inagaki, K., Inagaki, M., Kataoka, T., Sekido, I., Gill, M. A., & Nishida, M. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200212000-00007 · Cited by 29
Chronopharmacology of intravenous and oral modified release verapamil
Dilger, K., Eckhardt, K., Hofmann, U., Kucher, K., Mikus, G., & Eichelbaum, M. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00910.x · Cited by 27
Self-citationShinka, T., Naroda, T., Tamura, T., Sasahara, K., & Nakahori, Y. (2001) · Journal of Human Genetics · doi:10.1007/s100380170076 · Cited by 22
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“3, CYP3A4 shows significant activity and expression differences in females versus males (Wolbold et al., 2003; Cotreau et al., 2005; Lamba et al., 2010).”
BackgroundSelf-citationSex Differences in the Expression of Hepatic Drug Metabolizing Enzymes
Waxman, D. J., & Holloway, M. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056705 · Cited by 815
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Cytochrome P450-mediated metabolism of estrogens and its regulation in human
Tsuchiya, Y., Nakajima, M., & Yokoi, T. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.10.007 · Cited by 616
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Self-citation
Metadata
- Authors
- Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M.
- Venue
- Hepatology
- Published
- 2003-10
- Volume
- 38
- Issue
- 4
- Pages
- 978-988
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1997538585
- Cited by
- 529
- References
- 57
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.